Search Results for "pharmaceutical pricing"

19 result(s) found

Scroll Down To Discover

Found 19 result(s)

© Image Copyrights Juris Services & Technology

Bombay High Court Allows Petitions Challenging NPPA's Interpretation of DPCO 2013 — Price Ceiling Applicable Only to Formulations in First Schedule. The court held that NPPA cannot impose price ceiling on non-scheduled formulations under DPCO 2013, as the order's language is clear and unambiguous.

The petitioners, M/s. Franco Indian Pharmaceuticals Pvt. Ltd. and the Indian Drug Manufacturers Association (IDMA), challenged the interpretation and ...

© Image Copyrights Juris Services & Technology

Supreme Court Dismisses Appeal Against NPPA Demand for Overcharged Drug Prices. Appellant Held Liable as Distributor Under Paragraph 13 of DPCO 1995 Despite Claim of Being Only a Dealer.

The appellant, a pharmaceutical company, challenged demand notices issued by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs (Pri...

© Image Copyrights Juris Services & Technology

Supreme Court Upholds Drug Price Fixation Notifications for Frusemide and Theophylline Formulations. Price Fixation Under DPCO 1995 is a Legislative Exercise and Does Not Require Individual Hearing.

The appeals by special leave challenged the decision of the Allahabad High Court which had rejected writ petitions filed by the appellants, M/s T.C. H...

© Image Copyrights Juris Services & Technology

Bombay High Court Hears Challenge to Drug Price Control Demand Against Pharmaceutical Company. Cream Vs. Ointment Distinction and Small Scale Industry Exemption Under DPCO 1995 Considered.

The writ petition arose from a dispute concerning the drug price control regime under the Drugs (Price Control) Order, 1995 (DPCO 1995). The first pet...

© Image Copyrights Juris Services & Technology

Bombay High Court Dismisses Bayer's Challenge to Compulsory License for Nexavar Under Section 84 of Patents Act, 1970. Court Holds That Patentee's Import of Drug at High Price Does Not Satisfy Reasonable Requirements of Public or Constitute Working of Invention in India.

The petitioner, Bayer Corporation, a US-based pharmaceutical company, held a patent for the drug Sorafenib Tosylate, sold under the brand name Nexavar...

© Image Copyrights Juris Services & Technology

Bombay High Court Examines Constitutional Validity of Show Cause Notices Issued Under Repealed Drugs (Prices Control) Order, 1979. Petition Challenges Recovery of Alleged DPEA Liabilities Arising Under Paragraph 7(2) of DPCO 1979 Post-Repeal, Alleging Violation of Articles 14, 265, and 300A.

The writ petition was filed by Indian Drugs Manufacturers Association and Organization of Pharmaceutical Producers of India, acting on behalf of their...

© Image Copyrights Juris Services & Technology

Bombay High Court Dismisses Sun Pharma's Trademark Infringement Suit Against Sanofi's METOSAN, Finding No Deceptive Similarity with METOSARTAN. The marks are phonetically and visually distinct, and the products differ in composition, negating likelihood of confusion.

The plaintiff, Sun Pharma Laboratories Ltd, filed a suit for trademark infringement and passing off against The Madras Pharmaceuticals and Sanofi Indi...

© Image Copyrights Juris Services & Technology

Supreme Court Upholds Quashing of Notification Restricting Oxytocin Manufacture to Public Sector. Notification under Section 26A of Drugs and Cosmetics Act, 1940 held invalid for being arbitrary and disproportionate to the objective of curbing misuse.

The case involves a challenge to a notification issued by the Ministry of Health and Family Welfare under Section 26A of the Drugs and Cosmetics Act, ...